INDIANAPOLIS, September 29, 2017 /PRNewswire/ --
Changes include
addition of Information Technology to executive team; Two senior
leaders announce retirements
Eli Lilly and Company (NYSE: LLY) today announced a number of
leadership changes, promoting several experienced Lilly leaders to
executive roles, effective in 2018.
(Logo:
http://mma.prnewswire.com/media/479029/Eli_Lilly_and_Company_logo.jpg
)
- Josh Smiley has
been promoted to senior vice president and chief financial
officer and will become a member of Lilly's executive committee,
effective January 1, 2018. Lilly
announced in June that Derica Rice,
Lilly's current CFO, would retire at year-end.
- Dan Skovronsky, M.D.,
Ph.D., has been promoted to senior vice president for science and
technology and president of Lilly Research Labs and will become a
member of Lilly's executive committee. This change is effective
June 1, 2018.
- Myles O'Neill has been
promoted to senior vice president and president of manufacturing
operations and will become a member of Lilly's executive committee,
effective January 1, 2018.
- Aarti Shah, Ph.D., senior
vice president and chief information officer, has been named an
executive officer and will join Lilly's executive committee,
effective January 1, 2018.
Positioning the information technology function as a direct report
to the CEO is critical given the role digital technology and
analytics will play in the future of healthcare.
"Joining our executive team are individuals who have the
experience, expertise and leadership skills to build on our
momentum of innovation driven volume growth," said chairman and
chief executive officer, David A.
Ricks. "Importantly, this team will help us maintain focus
as we work to bring forward new medicines in diabetes, cancer,
immunology, neurodegeneration and pain and change the path of
serious disease."
"We are in a strong position today thanks to the incredible
commitment from all three of our executives who are announcing
retirements this year - Derica, whose retirement was announced in
June, as well as Maria Crowe and
Jan Lundberg," added Ricks. "They've
been a key part of our success over the last decade and today."
Crowe, Lundberg to retire
In addition to the appointments being announced today, two senior
leaders are announcing their retirement from the company.
Maria Crowe, president of
manufacturing operations, will retire in December 2017 after 35 years of service. She
joined Lilly in 1982 and since 2012 has led the company's global
manufacturing network of 14 sites on four continents. Previously,
she served as senior vice president global drug product
manufacturing, which included emerging markets manufacturing, drug
product operations and U.S. distribution. She also served as vice
president for drug product manufacturing in the U.S. and
Latin America; general manager of
Lilly del Caribe in Puerto Rico;
and general manager of Lilly's plant in Kinsale, Ireland.
"Maria has been a leader with tremendous impact throughout her
career - affecting nearly every aspect of Lilly manufacturing,"
said Ricks. "She has helped Lilly earn the trust of our customers,
making medicines with the highest levels of quality and safety, and
turning our scientists' life changing ideas into a reality."
Jan Lundberg, Ph.D.,
executive vice president for science and technology and president
of Lilly Research Labs, will retire at the end of May 2018 after eight years with Lilly. Prior to
joining Lilly he served for 10 years as global head of discovery
research at AstraZeneca. Lundberg's tenure marks a period of
tremendous R&D output with Lilly poised to launch as many as 20
new medicines in 10 years. The company improved late-stage success
rates and shortened the clinical development timelines under
Lundberg's leadership.
"Jan's leadership has pushed Lilly to address some of the most
challenging scientific questions head-on. Thanks to his
determination and commitment as a scientist and leader, we've seen
our pipeline of medicines grow significantly under his leadership,"
said Ricks. "Jan has positioned Lilly well for future success,
giving tremendous hope for patients."
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and www.lilly.com/newsroom/social-channels. C-LLY
Refer to:
Kelley Murphy; kmurphy@lilly.com ;
+1(317)701-4007 (Media)
Phil Johnson;
johnson_philip_l@lilly.com; +1(317) 655-6874 (Investors)
This is a disclosure announcement from PR Newswire.